-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 28 this year, Hengrui announced that the in-period analysis results of the phase analysis results of the main study endpoint of the phase III clinical (NCT03863860) study compared with placebo for the maintenance treatment of relapsed ovarian cancer reached the optimal standard set by the program.
a total of 252 subjects in the study were randomly assigned to the group on a 2:1 scale and were treated or orally with fluoroazole parri capsules or fluorine palipari analog capsules, respectively.
results showed that the single drug treatment of fluoroazole parri significantly prolonged the patient's progression-free survival.
December 14th, a new drug for the treatment of relapsed ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) with BRCA1/2 mutations was approved by NMPA.
addition, the treatment of ovarian, breast and pancreatic cancers with fluoroazole pills or co-apatinib is in phase III clinical studies.
there are a number of other combination therapies, including combination with abitron, combination with the anti-PD-L1 antibody SHR-1316 and temoazine to treat a variety of solid tumors is in clinical development.
currently has five PARP inhibitors approved for sale in the U.S., Lynparza, Rubraca, Zejula and Talzenna in the U.S., and Olapali in China in August 2018.
The toluene sulfonate Nirapali capsule, known as Nikolapali, was approved for listing in China in December 2019 for maintenance treatment in adult patients with platinum-sensitive relapsed epithelyl ovarian cancer, fallopian tube cancer or primary peritoneal cancer after platinum-containing chemotherapy has reached full or partial remission.
2019, Lynparza, Rubraca, Zejula and Talzenna will have global sales of approximately $1,357 million and U.S. sales of approximately $674 million.
, The cumulative investment in research and development costs of Hengrui Pharmaceutical Fluoropari is about 271.31 million yuan.
content Source: Medical Rubik's Cube Info